- Datametrex AI Limited (DM) has implemented a COVID-19 testing program for all employees and consultants
- The company is implementing both rapid testing and lab-based polymerase chain reaction testing
- These tests can detect the new variants
- Datametrex AI Limited is a technology-focused company
- Datametrex AI Limited opened trading at C$0.24 per share
Datametrex AI Limited (DM) has implemented an internal COVID-19 testing program.
This preventative program is for all the company employees, consultants, technicians, nurses, and lab partner employees.
Datametrex is implementing this testing protocol with both rapid testing and traditional lab-based polymerase chain reaction (PCR) testing.
The manufacturers have confirmed that these tests can detect the new variants.
With the increase in transmissible occurring with both the Brazil and UK variants, management felt it was prudent to increase the levels of testing to keep individuals in the company and community safe from contracting and inadvertently spreading the coronavirus.
Everyone in the company has also received training to monitor compliance to stop the spread of the coronavirus by wearing masks and including 2+2 movement restriction by keeping a distance of 2 metres from others whenever possible.
The testing will be managed by the company’s own trained nurses and processed by their lab partner technicians.
“The new Brazil and UK variants are highly contagious and spreading, management felt a significant need to improve the frequency and level of participation in providing COVID-19 testing for everyone in and around the company as part of the answer to keep people safe,” said Marshall Gunter, Chief Executive Officer, Datametrex AI Limited.
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy.
Datametrex AI Limited opened trading at C$0.24 per share.
